PTPRC and neoplasm: In CD45-enriched (EN) tumor (TU) cells (immune cells derived from tumor after anti-CD11b depletion and anti-CD45 column enrichment) were 30.80- and 192.72-fold higher compared with CD11bEN TU (immune cells derived from tumor cells after anti-CD11b column enrichment) and CD45-deprived (DEPR) TU cells (cells derived from tumor after anti-CD11b and anti-CD45 depletion), respectively (Figure 2D, right).